Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v8-EN | Version v1-EN | |
|---|---|---|
| Language | English | English |
| Date Updated | 2017-04-13 | 2017-03-22 |
| Drug Identification Number | 02139502 | 02139502 |
| Brand name | VASOPRESSIN INJECTION | VASOPRESSIN INJECTION |
| Common or Proper name | Vasopressin Injection, USP 20 units/mL MD Vial 1 mL | Vasopressin Injection, USP 20 units/mL MD Vial 1 mL |
| Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
| Ingredients | VASOPRESSIN | VASOPRESSIN |
| Strength(s) | 20UNIT | 20UNIT |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAMUSCULAR SUBCUTANEOUS | INTRAMUSCULAR SUBCUTANEOUS |
| Packaging size | 1mL | 1mL |
| ATC code | H01BA | H01BA |
| ATC description | POSTERIOR PITUITARY LOBE HORMONES | POSTERIOR PITUITARY LOBE HORMONES |
| Reason for shortage | Demand increase for the drug. | Demand increase for the drug. |
| Anticipated start date | ||
| Actual start date | 2017-02-16 | 2017-02-16 |
| Estimated end date | 2017-04-20 | Unknown |
| Actual end date | 2017-04-20 | |
| Shortage status | Actual shortage | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | Reduced allocation will no longer be in effect as of Thursday April 20th. Product will be available to all customers through all distribution channels without any volume restrictions. Please contact Fresenius Kabi Customer Service for further information. | On allocation at 75% of historical demand for all customers. Please contact Fresenius Kabi Customer Service for further information. |
| Health Canada comments |